05:19 PM EDT, 10/07/2024 (MT Newswires) -- (Rewrites throughout, adding new information from Pfizer's ( PFE ) response.)

Pfizer ( PFE ) prevailed in a UK court to invalidate two patents supporting GSK's (GSK) vaccine for respiratory syncytial virus, Pfizer ( PFE ) confirmed to MT Newswires Monday.

Pfizer ( PFE ) said in a statement that it was "pleased with the decision of the UK High Court finding certain GSK patents concerning RSV-related technology both invalid and not infringed."

The companies have been sparring in several jurisdictions as they have sought to market their respective RSV vaccines. GSK suing Pfizer ( PFE ) in August 2023 in a federal court in Delaware for infringement of four patents soon after Pfizer ( PFE ) won US regulatory approval for its Abrysvo vaccine.

The UK court ruling was reported earlier by Reuters.

GSK, which won US Food and Drug Administration for Arexvy in May 2023, told Reuters the ruling will have no impact on its ability to market Arexvy globally, including the UK. The company plans to appeal the decision.

GSK did not immediately respond to a message from MT Newswires seeking comment Monday afternoon.

Price: 29.21, Change: +0.01, Percent Change: +0.04